
Heather Payne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1493778/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet, The, 2020, 396, 1413-1421.	13.7	226
2	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. European Urology, 2017, 72, 521-531.	1.9	174
3	Impact of ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. Journal of Nuclear Medicine, 2018, 59, 89-92.	5.0	58
4	Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 593-601.	1.6	38
5	National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1253-1260.	0.8	38
6	Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 643-650.	27.6	27
7	Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. Lancet Oncology, The, 2021, 22, e207-e215.	10.7	20
8	National cohort study comparing severe mediumâ€ŧerm urinary complications after robotâ€assisted vs laparoscopic vs retropubic open radical prostatectomy. BJU International, 2018, 121, 445-452.	2.5	18
9	Impact of cancer service centralisation on the radical treatment of men with highâ€risk and locally advanced prostate cancer: A national crossâ€sectional analysis in England. International Journal of Cancer, 2019, 145, 40-48.	5.1	16
10	Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. Cancer Epidemiology, 2019, 63, 101628.	1.9	15
11	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	3.1	14
12	Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England. Journal of Clinical Oncology, 2020, 38, 744-752.	1.6	14
13	A European, prospective, observational study of enzalutamide in patients with metastatic castrationâ€resistant prostate cancer: PREMISE. International Journal of Cancer, 2022, 150, 837-846.	5.1	14
14	Management of locally advanced prostate cancer. Asian Journal of Andrology, 2009, 11, 81-87.	1.6	13
15	Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1219-1229.	0.8	13
16	Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. Cancer Epidemiology, 2019, 58, 44-51.	1.9	11
17	Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patientâ€reported outcomes. BJU International, 2022, 130, 84-91.	2.5	11
18	Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer, 2015, 13, e153-e158.	1.9	10

Heather Payne

#	Article	IF	CITATIONS
19	Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data. BJU International, 2017, 120, 219-225.	2.5	10
20	Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1196-1203.	0.8	10
21	Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. Radiotherapy and Oncology, 2018, 128, 357-363.	0.6	9
22	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. European Urology, 2022, 81, 598-605.	1.9	9
23	Patients' and partners' views of care and treatment provided for metastatic castrateâ€resistant prostate cancer in the UK. European Journal of Cancer Care, 2019, 28, e13140.	1.5	7
24	Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study. Radiotherapy and Oncology, 2021, 155, 48-55.	0.6	6
25	Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Prostate Cancer and Prostatic Diseases, 2023, 26, 257-263.	3.9	6
26	Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists Journal of Clinical Oncology, 2013, 31, 42-42.	1.6	4
27	Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uroâ€oncologists' opinions and practice. International Journal of Clinical Practice, 2019, 73, 1-6.	1.7	3
28	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer and Prostatic Diseases, 2023, 26, 287-292.	3.9	3
29	RADIATION IN HIGHâ€RISK PROSTATE CANCER: HOW MUCH IS ENOUGH?. BJU International, 2008, 102, 663-665	. 2.5	1
30	Second-line chemotherapy for advanced bladder cancer: A survey of current UK practice. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e11-52.e17.	1.6	1
31	Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e14338.	1.7	1
32	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical Genitourinary Cancer, 2022, , .	1.9	1
33	Interventions for obstructive uropathy in advanced prostate cancer: a populationâ€based study. BJU International, 2022, , .	2.5	1
34	Easing the journey through prostate cancer. British Journal of Health Care Management, 2010, 16, 129-133.	0.2	0
35	Anorectal toxicity of external beam radiotherapy in the treatment of prostate cancer. Journal of Clinical Urology, 2014, 7, 185-189.	0.1	0
36	Advances in advanced prostate cancer – the continuing journey. BJU International, 2016, 118, 17-19.	2.5	0

Heather Payne

#	Article	IF	CITATIONS
37	Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol 2019;76:228–37. European Urology, 2020, 77, e65.	1.9	0
38	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer—A UK perspective. International Journal of Clinical Practice, 2020, 74, e13611.	1.7	0
39	Management of newly diagnosed metastatic hormoneâ€sensitive prostate cancer: A survey of UK Uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e13874.	1.7	Ο
40	Current management and proposal for guidance of radiation cystitis (RC): Results of a British Uro-oncology Group (BUG) survey Journal of Clinical Oncology, 2013, 31, 297-297.	1.6	0